Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis.

Changes in Renal Profile Following SGLT2 Inhibitor Treatment in Diabetic Patients Figure 3 presents the assessment of the renal profile, showing an interesting trend towards a decrease in eGFR, only for male patients, following the initiation of SGLT2 inhibitor treatment (49 Q1–Q3: 28–73 vs. 43 Q1–Q3: 27.5–69; p -value < 0.05).

also in 1,431 other papers

Following the SGLT2 inhibitor treatment, there was an increasing trend in ALP levels for both female and male patients (female: 96 Q1–Q3: 74.25–123.75 vs. 100 Q1–Q3: 78–126; male: 91 Q1–Q3: 69–127 vs. 94 Q1–Q3: 70–130) ( p -value < 0.05).

also in 49,202 other papers

For the MCH, there was a marginally significant reduction post-treatment (29.25 Q1–Q3: 27.4–30.6) compared to values before the treatment initiation (29 Q1–Q3: 27.1–30.4) in male patients ( p -value < 0.05).

also in 21,285 other papers